Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Sanofi booked €26 million ($31 million) from the drug in the first three months of the year, with Regeneron recording $69 million in sales, although the partners both think that Libtayo as the ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable ...

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

Also Read: Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal By lowering AT, a protein that inhibits blood clotting, Qfitlia helps increase thrombin ...

About Regeneron and Sanofi’s COPD Clinical Research Program Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biotech companies create drugs from living organisms, requiring a BLA for FDA approval. Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and ...